Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Oral RT-111 (Ustekinumab) in Healthy Volunteers
NCT05890118Phase 1Completed
- Sponsor
- Rani Therapeutics
- Start
- Aug 2023
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ustekinumab in plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease and 1 more (3 arms), sponsored by Rani Therapeutics. Primary endpoints: Maximum Plasma Concentration at 60 days, Time to Maximum Plasma Concentration at 60 days and 1 more. Started Aug 2023; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05890118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890118.